Iovance Biotherapeutics (IOVA -1.2%) announces long-term follow-up data from cohort 2 in its Phase 2 C-144-01 study evaluating autologous tumor infiltrating lymphocyte (TIL) therapy lifileucel in metastatic melanoma patients.
Median duration of response has not been reached
after almost a median of 19 months. As of April, 23, the overall
response rate (ORR) was 36%, including two complete responders, with a
disease control rate (responders + stable cancer) of 80%.
Patients in cohort 2 were heavily pretreated with high baseline disease burden.
#ASCO20
https://seekingalpha.com/news/3578670-iovances-lifileucel-shows-sustained-benefit-in-melanoma-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.